Marine Cyanobacteria: A Source of Lead Compounds and their Clinically-Relevant Molecular Targets
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The prokaryotic filamentous marine cyanobacteria are photosynthetic microbes that are found in diverse marine habitats, ranging from epiphytic to endolithic communities. Their successful colonization in nature is largely attributed to genetic diversity as well as the production of ecologically important natural products. These cyanobacterial natural products are also a source of potential drug leads for the development of therapeutic agents used in the treatment of diseases, such as cancer, parasitic infections and inflammation. Major sources of these biomedically important natural compounds are found predominately from marine cyanobacterial orders Oscillatoriales, Nostocales, Chroococcales and Synechococcales. Moreover, technological advances in genomic and metabolomics approaches, such as mass spectrometry and NMR spectroscopy, revealed that marine cyanobacteria are a treasure trove of structurally unique natural products. The high potency of a number of natural products are due to their specific interference with validated drug targets, such as proteasomes, proteases, histone deacetylases, microtubules, actin filaments and membrane receptors/channels. In this review, the chemistry and biology of selected potent cyanobacterial compounds as well as their synthetic analogues are presented based on their molecular targets. These molecules are discussed to reflect current research trends in drug discovery from marine cyanobacterial natural products.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioactive natural products from marine cyanobacteria for drug discovery
Tan, L. T. (2007) · Phytochemistry · doi:10.1016/j.phytochem.2007.01.012 · Cited by 534
Self-citationTaori, K., Paul, V. J., & Luesch, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja7110064 · Cited by 428
Luesch, H., Yoshida, W. Y., Moore, R. E., Paul, V. J., & Corbett, T. H. (2001) · Journal of the American Chemical Society · doi:10.1021/ja010453j · Cited by 373
HDAC6 is a target for protection and regeneration following injury in the nervous system
Rivieccio, M. A., Brochier, C., Willis, D. E., Walker, B. A., D'Annibale, M. A., McLaughlin, K., Siddiq, A., Kozikowski, A. P., Jaffrey, S. R., Twiss, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907935106 · Cited by 322 · cited 1×
“Largazole analogues with selectivity for HDAC6 or HDAC10 have possible usage for the treatment of CNS disorders or ovarian cancer, respectively [48,49].”
BackgroundGroll, M., Kim, K. B., Kairies, N., Huber, R., & Crews, C. M. (2000) · Journal of the American Chemical Society · doi:10.1021/ja993588m · Cited by 304
Newman, D., & Cragg, G. (2014) · Marine Drugs · doi:10.3390/md12010255 · Cited by 250 · cited 1×
“For instance, a number of marine cyanobacterial compounds and their synthetic analogues formulated as Antibody-Drug Conjugates (ADCs), including dolastatin 10, auristatin E and OKI-179, have undergone/undergoing clinical trials for the treatment of cancer diseases [10,11].”
BackgroundMedina, R. A., Goeger, D. E., Hills, P., Mooberry, S. L., Huang, N., Romero, L. I., Ortega-Barría, E., Gerwick, W. H., & McPhail, K. L. (2008) · Journal of the American Chemical Society · doi:10.1021/ja801383f · Cited by 231
Cathepsins: Proteases that are vital for survival but can also be fatal
Patel, S., Homaei, A., El-Seedi, H. R., & Akhtar, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.148 · Cited by 224 · cited 1×
“However, dysregulated cathepsins have been implicated in a number of pathologies, including arthritis, periodontitis, pancreatitis, macular degeneration, muscular dystrophy, atherosclerosis, obesity, stroke, Alzheimer’s disease, schizophrenia, tuberculosis, and carcinogenesis [98].”
BackgroundLargazole: From discovery to broad-spectrum therapy
Hong, J., & Luesch, H. (2012) · Natural Product Reports · doi:10.1039/c2np00066k · Cited by 174
Marine cyanobacteria compounds with anticancer properties: A review on the implication of apoptosis
Costa, M., Costa-Rodrigues, J., Fernandes, M. H., Barros, P., Vasconcelos, V., & Martins, R. (2012) · Marine Drugs · doi:10.3390/md10102181 · Cited by 147
The dolastatins, a family of promising antineoplastic agents
Poncet, J. (1999) · Current Pharmaceutical Design · doi:10.2174/1381612805666230109214008 · Cited by 104
Zhou, H., Cai, Y., Liu, D., Li, M., Sha, Y., Zhang, W., Wang, K., Gong, J., Tang, N., Huang, A., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12447 · Cited by 85
Gunasekera, S. P., Miller, M. W., Kwan, J. C., Luesch, H., & Paul, V. J. (2010) · Journal of Natural Products · doi:10.1021/np900603f · Cited by 75
Boudreau, P. D., Miller, B. W., McCall, L.-I., Almaliti, J., Reher, R., Hirata, K., Le, T., Siqueira-Neto, J. L., Hook, V., & Gerwick, W. H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00294 · Cited by 57 · cited 3×
“Synthetic analogues of gallinamide A were recently explored as potent inhibitor of cathepsin L for the treatment of Ch gas disease [96].”
BackgroundInfluential
Cited by
Carroll, A. R., Copp, B. R., Davis, R. A., Keyzers, R. A., & Prinsep, M. R. (2022) · Natural Product Reports · doi:10.1039/d1np00076d · Cited by 269
Heterologous production of cyanobacterial compounds
Dhakal, D., Chen, M., Luesch, H., & Ding, Y. (2021) · Journal of Industrial Microbiology and Biotechnology · doi:10.1093/jimb/kuab003 · Cited by 33
Synthetic biology in marine cyanobacteria: Advances and challenges
Bourgade, B., & Stensjö, K. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.994365 · Cited by 28
Exploring cyanobacterial diversity for sustainable biotechnology
Selão, T. T. (2022) · Journal of Experimental Botany · doi:10.1093/jxb/erac053 · Cited by 15
Metadata
- Authors
- Tan, L. T., & Phyo, M. Y.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-08
- Volume
- 25
- Issue
- 9
- Pages
- 2197
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3023228103
- Cited by
- 65
- References
- 14
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.